AMYLIN PHARMACEUTICALS (AMLN) www.amylin.com

1
AMYLIN PHARMACEUTICALS (AMLN)
www.amylin.com Recent stock price 21.87
(1/19/04 close) 52-week range 13.73- 30.75
Market cap 2.04 Bil Revenue 13
Mil Expenses (119) Mil Net Loss (109) Mil
P/E N/A EPS -1.51 Estimated target
price 27.3 Amylin Pharmaceuticals, Inc. is a
biopharmaceutical company dedicated to developing
innovative medicines to improve the lives of
people with metabolic diseases. Estimated 177
Mil people worldwide suffer from diabetes, 18 Mil
of which have type I diabetes (juvenile,
autoimmune), and 159 Mil have type 2 (adult).
Approx. 11.5 Mil in U.S. have diabetes, with 1
Mil new cases each year.

10-Q 8K pos. results invest
for Exenatide _at_ 25
SEC
Exenatide PIII results reported
2
Amylin announces SEC investigation of conf. call
violation of Regulation FD
GS conf. Call Amylin CEO discusses FDA
rejection of Symlin
Club Biomed buys 200 shrs AMLN _at_ 25
Amylin announces positive P-III results for
Exenatide
3
January 2003-2004
AMLN v AMEX BIOTECH INDEX
AMLN v NASDAQ BIOTECH INDEX
4
PATENTS Hold 36 U.S. Patents and 33 pending U.S.
patent applications 17 issued to development
and commercialization of SYMLIN (10 pending) 1
issued to development and commercialization of
EXENATIDE (15 pending) Includes SYMLIN and
amylin analogs or agonists, methods of synthesis
for these molecules, methods of preparing these
products, BUT DO NOT have composition-of-matter
patent for EXENATIDE or EXENATIDE LAR.